Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - EyePoint Pharmaceuticals, Inc. | eypt-ex322_11.htm |
| EX-32.1 - EX-32.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex321_7.htm |
| EX-31.2 - EX-31.2 - EyePoint Pharmaceuticals, Inc. | eypt-ex312_9.htm |
| EX-31.1 - EX-31.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex311_8.htm |
| EX-21.1 - EX-21.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex211_13.htm |
| EX-10.36 - EX-10.36 - EyePoint Pharmaceuticals, Inc. | eypt-ex1036_284.htm |
| EX-10.35 - EX-10.35 - EyePoint Pharmaceuticals, Inc. | eypt-ex1035_845.htm |
| EX-10.19 - EX-10.19 - EyePoint Pharmaceuticals, Inc. | eypt-ex1019_531.htm |
| EX-4.5 - EX-4.5 - EyePoint Pharmaceuticals, Inc. | eypt-ex45_629.htm |
| 10-K - 10-K - EyePoint Pharmaceuticals, Inc. | eypt-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-152146, 333-163208, 333-216166, 333-227525, 333-233137 and 333-249902 on Form S-8 and Registration Nos. 333-226341, 333-228581, 333-252170 and 333-253053 on Form S-3 of our reports dated March 12, 2021, relating to the financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries appearing in this Annual Report on Form 10-K for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 12, 2021